Search results for "ErbB"

showing 10 items of 298 documents

Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides

2012

Irreversible epidermal growth factor receptor (EGFR) inhibitors contain a reactive warhead which covalently interacts with a conserved cysteine residue in the kinase domain. The acrylamide fragment, a commonly employed warhead, effectively alkylates Cys797 of EGFR, but its reactivity can cause rapid metabolic deactivation or nonspecific reactions with off-targets. We describe here a new series of irreversible inhibitors containing a 3-aminopropanamide linked in position 6 to 4-anilinoquinazoline or 4-anilinoquinoline-3- carbonitrile driving portions. Some of these compounds proved to be as efficient as their acrylamide analogues in inhibiting EGFR-TK (TK = tyrosine kinase) autophosphorylati…

AmideCell SurvivalEGFR inhibitorsQuinolineAntineoplastic AgentsAntineoplastic AgentStructure-Activity RelationshipT790MGefitinibCell Line TumorDrug DiscoveryPropionatemedicineHumansStructure–activity relationshipEpidermal growth factor receptorPhosphorylationAniline CompoundsbiologyChemistryDrug Discovery3003 Pharmaceutical ScienceAutophosphorylationQuinazolineAniline CompoundAmidesSettore CHIM/08 - Chimica FarmaceuticaErbB ReceptorsBiochemistryProtein kinase domainDrug Resistance NeoplasmQuinazolinesQuinolinesbiology.proteinMolecular MedicinePhosphorylationReceptor Epidermal Growth FactorPropionatesDrug Screening Assays AntitumorTyrosine kinaseHumanmedicine.drugJournal of Medicinal Chemistry
researchProduct

Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine

2012

Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member of the lipocalin family and has diverse roles. NGAL can stabilize matrix metalloproteinase-9 from autodegradation. NGAL is considered as a siderocalin that is important in the transport of iron. NGAL expression has also been associated with certain neoplasias and is implicated in the metastasis of breast cancer. In a previous study, we examined whether ectopic NGAL expression would alter the sensitivity of breast epithelial, breast and colorectal cancer cells to the effects of the chemotherapeutic drug doxorubicin. While abundant NGAL expression was detected in all the cells infected with a retrovirus encoding NGAL, t…

BenzylaminesBerberinemedicine.medical_treatmentDrug ResistanceGene ExpressionBCL-2; Berberine; Breast cancer; Calmodulin kinase; Colorectal cancer; EGFR; Inhibitor sensitivity; Lcn2; Lipocalins; NGAL; Rapamycin; Siderocalins; Targeted therapyPiperazinesMetastasisTargeted therapyNitrophenolsTargeted therapyBreast cancerAntibioticsNGALSulfonamidesAntibiotics AntineoplasticTumorSiderocalinsTyrphostinsAntineoplasticLipocalinsBiphenyl compoundErbB ReceptorsProto-Oncogene Proteins c-bcl-2MCF-7 CellsFemalelipocalinHT29 Cellsmedicine.drugbcl-2; breast cancer; lipocalins; targeted therapy; berberine; lcn2; colorectal cancer; rapamycin; inhibitor sensitivity; siderocalins; egfr; ngal; calmodulin kinaseCalmodulin kinasesiderocalinEGFRBCL-2Breast NeoplasmsSiderocalinBiologyNGAL Lcn2 lipocalins siderocalins targeted therapy inhibitor sensitivity EGFR rapamycin berberine BCL-2 calmodulin kinase breast cancer colorectal cancerCell LineHT29 CellsLcn2Lipocalin-2ReportCell Line TumorProto-Oncogene ProteinsmedicineHumansDoxorubicinRapamycinMolecular BiologyProtein Kinase InhibitorsSirolimusBiphenyl CompoundsCell Biologymedicine.diseaseColorectal cancerCell cultureDoxorubicinDrug Resistance NeoplasmCancer cellCalcium-Calmodulin-Dependent Protein KinasesCancer researchQuinazolinesNeoplasmInhibitor sensitivityDevelopmental BiologyAcute-Phase Proteins
researchProduct

Enhanced Gene Delivery by Avidin-Displaying Baculovirus

2004

Flexible alteration of virus surface properties would be beneficial for enhanced and targeted gene delivery. A useful approach could be based on a high-affinity receptor–ligand pair, such as avidin and biotin. In this study, we have constructed an avidin-displaying baculovirus, Baavi. Avidin display was expected to enhance cell transduction due to the high positive charge of avidin in physiological pH and to provide a binding site for covering the virus with desired biotinylated ligands. Successful incorporation of avidin on the virus envelope was detected by immunoblotting and electron microscopy. Multiple biotin-binding sites per virus were detected with fluorescence-correlation spectrosc…

Biotin bindingGenetic VectorsBiotinBiosensing TechniquesBiologyGene deliveryCell Linechemistry.chemical_compoundTransduction (genetics)BiotinViral envelopeTransduction GeneticCell Line TumorDrug DiscoveryGeneticsAnimalsBiotinylationBinding siteMolecular BiologyPharmacologyEpidermal Growth FactorGene Transfer TechniquesAvidinMolecular biologyCell biologyRatsErbB ReceptorsSpectrometry FluorescencechemistryBiotinylationbiology.proteinMolecular MedicineRabbitsBaculoviridaeViral Fusion ProteinsAvidinProtein BindingMolecular Therapy
researchProduct

Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: a case-control study.

2009

Objectives: Oral contraceptives (OCP) are highly effective, safe and widely used. Higher exposure to endogenous and exogenous estrogens is generally thought to increase the risk of breast cancer. Therefore, this study was conducted to determine if oral contraceptive use affected the expression of CA 15-3, CEA and C-erb B-2 in the saliva of healthy women. Study design: The participants consisted of 87 healthy women (43 controls and 44 using oral contraceptives) ranging in age from 20 to 54 years. The volunteers participated by giving one ? time stimulated whole saliva samples. Then the samples were analysed for CA 15-3, CEA and C-erb B-2 concentrations. Results: The student t-test was used t…

CA15-3Adultmedicine.medical_specialtySalivaReceptor ErbB-2PopulationPhysiologyYoung AdultBreast cancerMedicineEndocrine systemHumanseducationSalivaGeneral DentistryGynecologyeducation.field_of_studybusiness.industryMucin-1Case-control studyCancerMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCarcinoembryonic AntigenOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASSurgeryCancer biomarkersFemalebusinessContraceptives OralMedicina oral, patologia oral y cirugia bucal
researchProduct

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological c…

2022

Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates…

Cancer Research:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES]Lung NeoplasmsTesting:Biological Factors::Biomarkers [CHEMICALS AND DRUGS]:factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS]Targeted therapiesPulmons - Càncer:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES]Carcinoma Non-Small-Cell LungProto-Oncogene ProteinsGeneticsBiomarkers TumorHumansProspective StudiesCàncerDemographyReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesErbB ReceptorsOncologySpainPulmonsMarcadors bioquímicsBiomarkersMetastatic lung cancer
researchProduct

Abstract LB-399: Chronic inhibition of mutant EGFR in NSCLC leads to EGFR TKI resistance by TGF-β1 mediated epithelial to mesenchymal transition

2011

Abstract In NSCLC, activating EGFR mutations underlie responsiveness of NSCLCs to reversible EGFR tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib. Despite initial responses, acquired resistance invariably develops, mediated by the emergence of the secondary T790M mutation and by focal amplification of MET, in approximately 50% and 30% of patients, respectively. The resistance mechanisms for the remaining 20% of cases remain elusive. EGFR TKI-sensitive HCC827 cells were exposed to graded concentrations of erlotinib for 6 months. Approximately 70% of the isolated clones were resistant to erlotinib and harbored MET amplification, and were sensitive to dual EGFR/MET inhibit…

Cancer ResearchGene knockdownGrowth factormedicine.medical_treatmentBiologyPhenotyperespiratory tract diseasesT790MGefitinibOncologyImmunologymedicineCancer researchERBB3ErlotinibEpithelial–mesenchymal transitionmedicine.drugCancer Research
researchProduct

β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

2014

Abstract The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show that β-catenin is essential for development of EGFR-mutated lung cancers. β-Catenin was upregulated and activated in EGFR-mutated cells. Mutant EGFR preferentially bound to and tyrosine phosphorylated β-catenin, leading to an increase in β-catenin–mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Pharmacologic inhibition of β-catenin suppresse…

Cancer ResearchLung NeoplasmsCarcinogenesisAfatinibMutation MissenseAntineoplastic AgentsMice TransgenicAfatinibmedicine.disease_causeArticleTransactivationGefitinibCarcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansEpidermal growth factor receptorLung cancerbeta CateninMutationbiologyProtein Stabilitymedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenUp-Regulationrespiratory tract diseasesErbB ReceptorsGene Expression Regulation NeoplasticHEK293 CellsOncologyDoxycyclineCateninImmunologyQuinazolinesCancer researchbiology.proteinCarcinogenesismedicine.drugCancer Research
researchProduct

Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment r…

2012

Abstract Patients with lung cancer with activating mutations in the EGF receptor (EGFR) kinase, who are treated long-term with tyrosine kinase inhibitors (TKI), often develop secondary mutations in EGFR associated with resistance. Mice engineered to develop lung adenocarcinomas driven by the human EGFR T790M resistance mutation are similarly resistant to the EGFR TKI erlotinib. By tumor volume endpoint analysis, these mouse tumors respond to BIBW 2992 (an irreversible EGFR/HER2 TKI) and rapamycin combination therapy. To correlate EGFR-driven changes in the lung with response to drug treatment, we conducted an integrative analysis of global transcriptome and metabolite profiling compared wit…

Cancer ResearchLung NeoplasmsCombination therapyAfatinibGene ExpressionAdenocarcinoma of LungCell Growth ProcessesAdenocarcinomaAfatinibArticleErlotinib HydrochlorideMiceAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsEpidermal growth factor receptorLung cancerErlotinib HydrochlorideProtein Kinase InhibitorsSirolimusbiologymedicine.diseaserespiratory tract diseasesErbB ReceptorsOncologyTumor progressionDrug Resistance NeoplasmCancer researchbiology.proteinDisease ProgressionQuinazolinesErlotinibTyrosine kinasemedicine.drugTranscription FactorsCancer research
researchProduct

Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer

2013

Abstract Background The human ERBB2 gene is frequently amplified in breast tumors, and its high expression is associated with poor prognosis. We previously reported a significant inverse correlation between Myc promoter-binding protein-1 (MBP-1) and ERBB2 expression in primary breast invasive ductal carcinoma (IDC). MBP-1 is a transcriptional repressor of the c-MYC gene that acts by binding to the P2 promoter; only one other direct target of MBP-1, the COX2 gene, has been identified so far. Methods To gain new insights into the functional relationship linking MBP-1 and ERBB2 in breast cancer, we have investigated the effects of MBP-1 expression on endogenous ERBB2 transcript and protein lev…

Cancer ResearchMBP-1/EnolaseReceptor ErbB-2Breast NeoplasmsHistone Deacetylase 1BiologyERBB geneBreast cancerTranscriptional regulationTranscription (biology)Histone DeacetylaseBreast CancermedicineTranscriptional regulationBiomarkers TumorTumor Cells CulturedGeneticsHumansMBP-1ERBB2Promoter Regions Geneticskin and connective tissue diseasesGeneReporter geneCarcinoma Ductal BreastCancerTransfectionGenes erbB-2medicine.diseaseImmunohistochemistryHDAC1Neoplasm ProteinsDNA-Binding ProteinsGene Expression Regulation NeoplasticSettore BIO/18 - GeneticaOncologyCancer researchChromatin immunoprecipitationResearch ArticleBMC Cancer
researchProduct

Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor

2019

BACKGROUND The oncogenic role of epidermal growth factor receptor (EGFR) has been intensively studied. However, its emerging role in drug resistance has not been fully addressed. MATERIALS AND METHODS This study systematically investigated the correlation of mRNA and protein expression of EGFR, as well as gene amplification and mutations with the log-transformed half-maximal inhibitory concentration (log10IC50) values obtained from the NCI panel of 60 human tumor cell lines against 83 standard anticancer agents and the top 10 natural cytotoxic products previously screened by us. RESULTS EGFR protein expression, rather than other measurements, was most frequently associated with drug respons…

Cancer ResearchOncogenebiologyChemistryTopoisomeraseAntineoplastic AgentsGeneral MedicineDrug resistanceErbB Receptors03 medical and health sciences0302 clinical medicineOncologyDrug Resistance NeoplasmCell cultureCell Line TumorNeoplasms030220 oncology & carcinogenesisPharmacogenomicsbiology.proteinCancer researchHumansCytotoxic T cellRNA MessengerEpidermal growth factor receptorCross-resistanceAnticancer Research
researchProduct